We are live on ! Find out more
IFRX icon

InflaRx

46 hedge funds and large institutions have $548M invested in InflaRx in 2019 Q1 according to their latest regulatory filings, with 17 funds opening new positions, 17 increasing their positions, 7 reducing their positions, and 5 closing their positions.

New
Increased
Maintained
Reduced
Closed

240% more first-time investments, than exits

New positions opened: 17 | Existing positions closed: 5

143% more repeat investments, than reductions

Existing positions increased: 17 | Existing positions reduced: 7

35% more funds holding

Funds holding: 3446 (+12)

14% more capital invested

Capital invested by funds: $482M → $548M (+$66.7M)

4.84% more ownership

Funds ownership: 51.05%55.89% (+4.8%)

20% less funds holding in top 10

Funds holding in top 10: 54 (-1)

Holders
46
Holders Change
+12
Holders Change %
+35.29%
% of All Funds
1%
Holding in Top 10
4
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-20%
% of All Funds
0.09%
New
17
Increased
17
Reduced
7
Closed
5
Calls
Puts
Net Calls
Net Calls Change
Name Holding Trade Value Shares
Change
Change in
Stake
Squarepoint
51
Squarepoint
New York
-$258K -7,100 Closed

IFRX Hedge Fund Activity: Q1 2019 in Review

46 of the 4,621 institutional investors tracked by Wall St. Rank reported a position in InflaRx (IFRX) for Q1 2019, worth a combined $548M — up 14% from $482M a quarter earlier.

Buyers outnumbered sellers: 17 funds opened new IFRX positions and 5 closed out — a net gain of 12 holders — while 17 added to existing stakes and 7 trimmed.

The largest buyer was Cormorant Asset Management, adding an estimated $41.5M. The largest seller was Bain Capital Life Sciences Investors, cutting an estimated $38.5M.

  • 46 institutional investors held InflaRx (IFRX) as of Q1 2019, up from 34 in Q4 2018.
  • Funds reported $548M of InflaRx stock for Q1 2019, up 14% quarter-over-quarter.
  • 17 funds opened new InflaRx positions in Q1 2019 and 5 closed out, a net change of +12 holders.
  • The largest InflaRx buyer in Q1 2019 was Cormorant Asset Management, an estimated $41.5M added.
  • The largest InflaRx seller in Q1 2019 was Bain Capital Life Sciences Investors, an estimated $38.5M sold.

Based on aggregated 13F filings for Q1 2019.